{"_id": "64e29bf971a8c404a9d437b4", "nctid": "NCT02973750", "title": "Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology", "eligibilityCriteria": {"$and": [{"$and": [{"$or": [{"histological or cytological diagnosis of high-grade serous ovarian, fallopian, or peritoneal cancer, stage III or IV": true}, {"$and": [{"highly suspicious stage III or IV ovarian, fallopian, or peritoneal cancer": true}, {"$not": {"histologically confirmed non-serous ovarian, fallopian, and peritoneal cancers": true}}]}]}, {"at least one biopsiable lesion by CT/US or laparoscopy": true}, {"$not": {"previous treatment for ovarian cancer": true}}, {"life expectancy greater than 6 months": true}, {"ECOG performance status": {"$lt": 3}}, {"adequate organ and marrow function": true}, {"deemed eligible for neo-adjuvant chemotherapy with carboplatin and paclitaxel and surgery by their oncologist": true}, {"$or": [{"women of child-bearing potential agree to use adequate contraception prior to study entry and for the duration of study participation": true}, {"$not": {"women of child-bearing potential": true}}]}, {"ability to understand and the willingness to sign a written informed consent document": true}]}, {"$not": {"$or": [{"active second malignancy within last 2 years": {"$not": {"$or": ["non-melanoma skin cancer", "in situ carcinomas"]}}}, {"$not": {"prior treatment for ovarian cancer": true}}, {"$not": {"known brain metastases": true}}, {"history of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin and paclitaxel": true}, {"known allergy to carboplatin, paclitaxel, or cremophor": true}, {"uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements": true}, {"$or": [{"women who are pregnant": true}, {"$and": [{"women who are breastfeeding": true}, {"treated with carboplatin and paclitaxel": true}]}]}, {"$and": [{"HIV-positive patients receiving combination anti-retroviral therapy": true}, {"$not": {"possible pharmacokinetic interactions with carboplatin and paclitaxel or other agents administered during the study": true}}]}]}}]}, "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": {"$gte": 18}, "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Female cancer patients age 18 years or older, with at least one third of the participants to be aged 70 years or more. Participants must have high-grade serous ovarian, fallopian, or peritoneal cancer, stage III or IV. Women and members of all races and ethnic groups are eligible for this trial. The study is not relevant to men.\n\nWith a sample of 50 patients, investigators can detect a correlation as strong as 0.38 between body composition and AUC of carboplatin and paclitaxel with a power of 0.80 at the significance level of 0.05. In order to allow for a 10% drop out/incompletion rate, investigators will accrue 55 participants.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}